SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
IQVIA Holdings Inc.
IQV
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Last trade$259.01
Day change-$5.72 (-2.16%)
Day range$258.02 – $265.75
Volume842,076
Market cap$43.63B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$43.63B
Price / earnings
31.3×
Price / book
6.55×
Price / sales
2.52×
EV / sales
3.32×
EV / EBITDA
15.91×
Profitability
Earnings per share
$8.46
Return on assets
4.57%
Return on equity
20.93%
Dividend yield
0%
Liquidity and leverage
Debt / equity
2.41×
Current ratio
0.83×
Quick ratio
0.83×
Cash ratio
0.29×
Cash flow
Price / cash flow
15.95×
Price / free cash flow
20.98×
Free cash flow
$2.08B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IQV, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$4.43B
$4.37B
$4.15B
$4.36B
$4.1B
$4.02B
$3.83B
$3.96B
Cost of revenue
$2.93B
$2.93B
$2.8B
$2.93B
$2.73B
$2.69B
$2.53B
$2.58B
Gross profit
$1.5B
$1.44B
$1.36B
$1.44B
$1.37B
$1.32B
$1.3B
$1.38B
Selling, general and administrative
$569M
$574M
$502M
$468M
$514M
$509M
$508M
$453M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$926M
$929M
$841M
$809M
$820M
$817M
$802M
$752M
Operating income
$572M
$506M
$514M
$627M
$553M
$506M
$496M
$626M
Interest expense
-$203M
-$197M
-$192M
-$193M
-$189M
-$182M
-$165M
-$171M
Income before taxes
$386M
$318M
$328M
$537M
$408M
$322M
$323M
$544M
Income taxes
$76M
$60M
$59M
$59M
$76M
$56M
$61M
$112M
Net income
$352M
$258M
$275M
$514M
$332M
$266M
$249M
$437M
Net income attributable to common shareholders
$350M
$256M
$274M
$514M
$331M
$266M
$249M
$437M
EBITDA
$929M
$861M
$853M
$968M
$859M
$814M
$790M
$925M
Basic earnings per share
$2.13
$1.54
$1.63
$3.03
$1.94
$1.55
$1.42
$2.44
Diluted earnings per share
$2.10
$1.53
$1.61
$2.99
$1.93
$1.54
$1.40
$2.42
Recent news
Company coverage with links to the original publishers.
IQVIA Holdings (IQV) reported solid Q3 2026 results with R&D Solutions revenues up 8.7% year-over-year and net new bookings growing 15%, while Commercial Solutions revenues grew 6.9%. The company's deployment of 415 AI agents has improved operational efficiency, with adjusted EBITDA rising 8.7% and margins expanding by 20 basis points. Despite strong performance, IQV holds a Zacks Rank #3 (Hold) rating.
IQVIA Holdings reported strong Q3 2026 results with adjusted EPS of $3.34 (up 11.3% YoY) and revenues of $4.43B (up 8% YoY), both beating consensus estimates. R&D bookings jumped 15% to $3.2B with strongest clinical bookings since 2022. The company raised its 2026 revenue guidance to $17.35-$17.50B and adjusted EPS guidance to $12.90-$13.00. However, operating costs remain elevated and the stock carries a Zacks Rank #4 (Sell) rating.
AxoGen is expected to report Q3 2026 earnings of $0.14 per share with 21.2% revenue growth on October 28, but carries a 0% Earnings ESP with a Zacks Rank #2, making it difficult to predict an earnings beat. Meanwhile, IQVIA is projected to post $3.24 EPS with 6.4% revenue growth, but faces a negative Earnings ESP of -0.09% combined with a Zacks Rank #4 (Sell), suggesting limited upside potential despite a history of beating estimates.
IQVIA Holdings is expected to report Q3 2026 earnings on October 27, with consensus estimates of $3.24 EPS (up 8% YoY) and $4.36B in revenues (up 6.4% YoY). However, recent analyst revisions have turned slightly bearish, resulting in a negative Earnings ESP of -0.09%, making it difficult to predict an earnings beat despite the company's strong historical track record of beating estimates in the last four quarters.
Veeva Systems expanded its partnership with IQVIA, with IQVIA selecting additional Veeva clinical operations applications as enterprise standards for clinical development studies. The agreement covers CTMS, eTMF, Study Startup, and Site Connect tools, building on their previous EDC partnership. This expansion is expected to strengthen Veeva's presence in clinical research, improve trial efficiency, and create cross-selling opportunities, though financial terms and deployment timelines were not disclosed.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.